Learn how to develop a Talk to Your Graph (TTYG) client by integrating GraphDB and the OpenAI Assistants API Continue Reading Talk to Your Graph Client for GraphDB
Archive for "Featured"
How Far We Can Go with GenAI as an Information Extraction Tool
How we used Ontotext GraphDB and LLMs to improve CV selection Continue Reading How Far We Can Go with GenAI as an Information Extraction Tool
Accelerating Drug Discovery with AI-based Gene-Disease Link Predictions
Read about how predicted links between genes and disease relations can help speed up target validation, drug development and provide novel insights into disease biology Continue Reading Accelerating Drug Discovery with AI-based Gene-Disease Link Predictions
My Dear Watson, it is Great to Have Someone to Talk to
Join us to learn how we empower users to sift through a large pool of data with the help of a trusted assistant – the GraphDB 10.8 Talk To Your Graph agent. Continue Reading My Dear Watson, it is Great to Have Someone to Talk to
Lower Your Large Language Model Costs with Graphwise GraphDB
Learn about why GraphDB can help lower the cost of LLMs in production as compared to a pure vector database-based approach. Continue Reading Lower Your Large Language Model Costs with Graphwise GraphDB
Semantization of Regulatory Documents in AECO
Learn how knowledge graphs combined with the latest natural language processing technologies aid regulatory information extraction and processing from unstructured data. Continue Reading Semantization of Regulatory Documents in AECO
Advancing Automatic Knowledge Extraction with PubMiner AI
PubMiner AI aims to help researchers in the biomedical domain overcome the challenges in automatic knowledge extraction from large volumes of scientific publications. Continue Reading Advancing Automatic Knowledge Extraction with PubMiner AI
Speeding Up Cancer Research with Target Discovery: An Interview with a Global Top 10 Early Drug R&D Center
How we used Ontotext GraphDB and LLMs to improve CV selection Continue Reading Speeding Up Cancer Research with Target Discovery: An Interview with a Global Top 10 Early Drug R&D Center